The Cologuard Plus test demonstrated 95% sensitivity for colorectal cancer detection at 94% specificity, making it the most accurate noninvasive CRC screening test reported in studies to date ...

(RTTNews) - Exact Sciences Corp. (EXAS) Monday has introduced Cologuard Plus, an FDA-approved noninvasive colorectal cancer - CRC screening test for average-risk adults aged 45 and older.

Exact Sciences (EXAS) announced the launch of Cologuard Plus, which it calls “the most accurate noninvasive colorectal cancer screening test reported in studies to date.” The company added ...